Literature DB >> 24442606

Progressive multifocal leukoencephalopathy after natalizumab discontinuation: few and true?

Mike P Wattjes1, Joep Killestein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24442606     DOI： 10.1002/ana.24110

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


× No keyword cloud information.
  9 in total

Review 1.  Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients.

Authors:  Mike P Wattjes; Àlex Rovira; David Miller; Tarek A Yousry; Maria P Sormani; Maria P de Stefano; Mar Tintoré; Cristina Auger; Carmen Tur; Massimo Filippi; Maria A Rocca; Franz Fazekas; Ludwig Kappos; Chris Polman
Journal:  Nat Rev Neurol       Date:  2015-09-15       Impact factor: 42.937

Review 2.  Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis.

Authors:  Jens Ingwersen; Orhan Aktas; Hans-Peter Hartung
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 3.  Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 2-Surveillance for Treatment Complications and Disease Progression.

Authors:  C McNamara; G Sugrue; B Murray; P J MacMahon
Journal:  AJNR Am J Neuroradiol       Date:  2017-04-20       Impact factor: 3.825

4.  Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?

Authors:  Mike P Wattjes; Anke Vennegoor; Jop Mostert; Bob W van Oosten; Frederik Barkhof; Joep Killestein
Journal:  J Neurol       Date:  2014-04-06       Impact factor: 4.849

Review 5.  Disease-modifying therapies and infectious risks in multiple sclerosis.

Authors:  Alexander Winkelmann; Micha Loebermann; Emil C Reisinger; Hans-Peter Hartung; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2016-03-04       Impact factor: 42.937

Review 6.  Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications.

Authors:  Mark S Igra; David Paling; Mike P Wattjes; Daniel J A Connolly; Nigel Hoggard
Journal:  Br J Radiol       Date:  2017-04-26       Impact factor: 3.039

Review 7.  Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities.

Authors:  Justin M Honce; Lidia Nagae; Eric Nyberg
Journal:  Mult Scler Int       Date:  2015-09-21

8.  PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation.

Authors:  J Killestein; A Vennegoor; A E L van Golde; R L J H Bourez; M L B Wijlens; M P Wattjes
Journal:  Case Rep Neurol Med       Date:  2014-11-23

9.  Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis.

Authors:  Luca Prosperini; Revere P Kinkel; Augusto A Miravalle; Pietro Iaffaldano; Simone Fantaccini
Journal:  Ther Adv Neurol Disord       Date:  2019-03-29       Impact factor: 6.570
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.